Effectiveness and safety of didanosine, lamivudine and efavirenz versus zidovudine, lamivudine and efavirenz for the initial treatment of HIV-infected patients from the Spanish VACH cohort

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 1, 2009, Pages 189-196

  Crespo, Manuel ^a   Ribera, Esteban ^a   Suárez Lozano, Ignacio ^b   Domingo, Pere ^c   Pedrol, Enric ^d   López Aldeguer, José ^e   Muñoz, Agustín ^f   Viladés, Consuelo ^g   Sánchez, Trinitario ^h   Viciana, Pompeyo ⁱ   Teira, Ramón ^j   García Alcalde, María Luisa ^k   Vergara, Antonio ^l   Lozano, Fernándo ^m   Galindo, María José ⁿ   Cosin, Jaime ^o   Roca, Bernardino ^p   Terrón, Alberto ^q   Geijo, Paloma ^r   Vidal, Francesc ^g   Garrido, Myriam ^s   more..

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^b HOSPITAL INFANTA ELENA   (Spain)

^c HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^d HOSPITAL GENERAL DE GRANOLLERS   (Spain)

^e HOSPITAL UNIVERSITARIO LA FE   (Spain)

^f HOSPITAL INFANTA CRISTINA   (Spain)

^g HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^h Hospital Virgen del Rosell   (Spain)

ⁱ HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^j HOSPITAL DE BASURTO   (Spain)

^k HOSPITAL DE CABUEÑES   (Spain)

^l HOSPITAL UNIVERSITARIO DE PUERTO REAL   (Spain)

^m HOSPITAL UNIVERSITARIO DE VALME   (Spain)

ⁿ HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^o HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^p HOSPITAL GENERAL DE CASTELLÓN   (Spain)

^q Hospital del SAS   (Spain)

^r HOSPITAL VIRGEN DE LA LUZ   (Spain)

^s Data Management VACH Group   (Spain)

more..

Author keywords

Naive patients; Nucleoside reverse transcriptase inhibitors; Observational cohort study; Once a day regimen

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE PLUS EFAVIRENZ PLUS LAMIVUDINE; EFAVIRENZ PLUS LAMIVUDINE PLUS ZIDOVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BEDTIME DOSAGE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG TOLERANCE; DRUG TREATMENT FAILURE; FEMALE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEUKOCYTE DIFFERENTIAL COUNT; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; OBSERVATIONAL STUDY; RISK FACTOR; SIDE EFFECT; SPAIN; TREATMENT DURATION; TRIACYLGLYCEROL BLOOD LEVEL;

ADULT; ANTI-HIV AGENTS; BENZOXAZINES; COHORT STUDIES; DIDANOSINE; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; LAMIVUDINE; MALE; PROSPECTIVE STUDIES; SPAIN; TREATMENT OUTCOME;

EID: 57649205355     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkn450     Document Type: Article

References (29)

1. Bartlett JA, Fath MJ, Demasi R et al. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS 2006; 20: 2051-64.
2. Lucas GM, Chaisson RE, Moore RD. Highly active antiretroviral therapy in a large urban clinic: Risk factors for virologic failure and adverse drug reactions. Ann Intern Med 1999; 131: 81-7.
3. U.S. Department of Health and Human Services. Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents - January 29, 2008. http://www.aidsinfo.nih.gov/Guidelines/ (12 February, date last accessed).
4. Hammer SM, Saag MS, Schechter M et al. Treatment for adult HIV infection: 2006 recommendations of the International AIDS Society-USA panel. JAMA 2006; 296: 827-43.
5. Gazzard B. British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy. HIV Med 2005; 6 Suppl 2: 1-61.
6. Recommendations from the GESIDA/Spanish AIDS Plan regarding antiretroviral treatment in adults infected by the human immunodeficiency virus infection (updated January 2007). Enferm Infecc Microbiol Clin 2007; 25: 32-53.
7. Landman R, Schiemann R, Thiam S et al. Once-a-day highly active antiretroviral therapy in treatment-naive HIV-1-infected adults in Senegal. AIDS 2003; 17: 1017-22.
8. Maggiolo F, Migliorino M, Maserati R et al. Virological and immunological responses to a once-a-day antiretroviral regimen with didanosine, lamivudine and efavirenz. Antivir Ther 2001; 6: 249-53.
9. Santos J, Palacios R, Lopez M et al. Simplicity and efficacy of a once-daily antiretroviral regimen with didanosine, lamivudine, and efavirenz in naive patients: The VESD study. HIV Clin Trials 2005; 6: 320-8.
10. Maggiolo F, Ripamonti D, Gregis G et al. Once-a-day therapy for HIV infection: A controlled, randomized study in antiretroviral-naive HIV-1-infected patients. Antivir Ther 2003; 8: 339-46.
11. Berenguer J, González J, Ribera E et al. Didanosine, lamivudine and efavirenz vs. zidovudine, lamivudine and efavirenz for initial treatment of HIV infection over 48 weeks: A randomized non-inferiority clinical trial, GESIDA 3903. In: Abstracts of the Forty-Seventh Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, 2007. Abstract H-363. American Society for Microbiology,Washington, DC, USA.
12. Pulido F, Ribera E, Moreno S et al. Once-daily antiretroviral therapy: Spanish Consensus Statement. J Antimicrob Chemother 2005; 56: 808-18.
13. Sabin C, Worm S, Weber R et al. Do thymidine analogues, abacavir, didanosine and lamivudine contribute to the risk of myocardial infarction? The D:A:D study. In: Abstracts of the Fifteenth Conference on Retroviruses and Opportunistic Infections, Boston, MA, 2008. Abstract 957c. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
14. Squires K, Lazzarin A, Gatell JM et al. Comparison of once-daily atazanavir with efavirenz, each in combination with fixed-dose zidovudine and lamivudine, as initial therapy for patients infected with HIV. J Acquir Immune Defic Syndr 2004; 36: 1011-9.
15. Staszewski S, Morales-Ramirez J, Tashima KT et al. Efavirenz plus zidovudine and lamivudine, efavirenz plus indinavir, and indinavir plus zidovudine and lamivudine in the treatment of HIV-1 infection in adults. Study 006 Team. N Engl J Med 1999; 341: 1865-73.
16. Pozniak AL, Gallant JE, DeJesus E et al. Tenofovir disoproxil fumarate, emtricitabine, and efavirenz versus fixed-dose zidovudine/ lamivudine and efavirenz in antiretroviral-naive patients: Virologic, immunologic, and morphologic changes - a 96-week analysis. J Acquir Immune Defic Syndr 2006; 43: 535-40.
17. DeJesus E, Herrera G, Teofilo E et al. Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviralnaive HIV-infected adults. Clin Infect Dis 2004; 39: 1038-46.
18. Gallant JE, DeJesus E, Arribas JR et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med 2006; 354: 251-60.
19. Moyle GJ, Sabin CA, Cartledge J et al. A randomized comparative trial of tenofovir DF or abacavir as replacement for a thymidine analogue in persons with lipoatrophy. AIDS 2006; 20: 2043-50.
20. Peyriere H, Reynes J, Rouanet I et al. Renal tubular dysfunction associated with tenofovir therapy: Report of 7 cases. J Acquir Immune Defic Syndr 2004; 35: 269-73.
21. Karras A, Lafaurie M, Furco A et al. Tenofovir-related nephrotoxicity in human immunodeficiency virus-infected patients: Three cases of renal failure, Fanconi syndrome, and nephrogenic diabetes insipidus. Clin Infect Dis 2003; 36: 1070-3.
22. Symonds W, Cutrell A, Edwards M et al. Risk factor analysis of hypersensitivity reactions to abacavir. Clin Ther 2002; 24: 565-73.
23. Damle BD, Yan JH, Behr D et al. Effect of food on the oral bioavailability of didanosine from encapsulated enteric-coated beads. J Clin Pharmacol 2002; 42: 419-27.
24. Hernandez-Novoa B, Antela A, Gutierrez C et al. Effect of food on the antiviral activity of didanosine enteric-coated capsules: A pilot comparative study. HIV Med 2008; 9: 187-91.
25. Whitcomb JM, Parkin NT, Chappey C et al. Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates. J Infect Dis 2003; 188: 992-1000.
26. Maggiolo F, Ripamonti D, Torti C et al. The effect of HIV-1 resistance mutations after first-line virological failure on the possibility to sequence antiretroviral drugs in second-line regimens. Antivir Ther 2006; 11: 923-9.
27. Antinori A, Trotta MP, Nasta P et al. Antiviral efficacy and genotypic resistance patterns of combination therapy with stavudine/ tenofovir in highly active antiretroviral therapy experienced patients. Antivir Ther 2006; 11: 233-43.
28. D'Agostino RB Jr. Propensity score methods for bias reduction in the comparison of a treatment to a non-randomized control group. Stat Med 1998; 17: 2265-81.
29. Phillips AN, Grabar S, Tassie JM et al. Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: Comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups. AIDS 1999; 13: 2075-82.